Medrio contracted ISR to survey industry experts involved in Phase I research across North America and Europe to understand how they leverage technology.
Based on responses from 88 individuals working in Phase I clinical trials, it’s clear that early phase studies vary dramatically among companies. However, respondents all had one thing in common: they needed flexibility and expert guidance from their technology partners.
This report includes the research results and industry expert insights that explore the “why” behind the data. It highlights and discusses three major findings:
- How increasing variables affect early phase research
- How sponsors navigate the pressure to move quickly
- Why creating a cohesive data strategy is challenging
Contributing Experts at Medrio:
- Ana Palijan, Director of Early Phase and Translation Research at Innovaderm Research
- Courtnay Buonomo, Associate Director of Data Management Systems and Standards at ADARx Pharmaceuticals
- Éric Hardy, Senior Director Biometrics​ at Innovaderm Research
- Nicole Latimer, CEO at Medrio